Editas Medicine appoints Dan Ory as chief medical officer

PUBT · 1d ago
Editas Medicine appoints Dan Ory as chief medical officer
  • Editas Medicine appointed Dan Ory as chief medical officer, effective today.
  • Ory will lead clinical development as Editas advances EDIT-401, an in vivo gene-editing candidate for hyperlipidemia, toward the clinic.
  • He previously served as chief medical officer at Arbor Biotechnologies, overseeing a global clinical trial for an in vivo gene-editing program.
  • Earlier roles include chief medical officer at Casma Therapeutics, leading clinical programs in rare genetic and neurodegenerative diseases.
  • Ory spent more than two decades at Washington University School of Medicine, researching cholesterol metabolism and Niemann-Pick disease type C.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080700PRIMZONEFULLFEED9822445) on September 08, 2026, and is solely responsible for the information contained therein.